BioNTech to Acquire Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD

MAINZ, Germany & Santa Monica, USA, July 19, 2021 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) und Kite, a Gilead Company (Nasdaq: GILD, “Kite”) today announced the two companies have entered into a purchase agreement for BioNTech to acquire Kite’s solid tumor...

Click to view original post